NVE Corp Stock Falls 33% After Y/Y Earnings Decline in Q2

NVE Corp fell 33% after fiscal Q2 2027 revenue declined 8% year over year to $5.83 million, net income fell 4% to $3.17 million and EPS slipped to $0.65 from $0.68; defense product sales dropped 95%. First-half revenue nevertheless rose 36% to $16.9 million and net income increased 39% to $9.57 million, with $11.1 million of operating cash flow. Management expects medical-device and defense sales to recover in Q3 and second-half revenue to remain broadly consistent with first-half levels; the company also declared a $1-per-share quarterly dividend.

Analysis

The selloff may be pricing a one-quarter interruption as a broken growth story, but the operating signal is mixed: distributor growth and first-half expansion are encouraging, while a major medical customer’s inventory adjustment and volatile defense orders show how a small revenue base can swing sharply. Distributor orders are not proof of end-customer sell-through; a reversal in restocking could erase that support. New sensor design wins are a longer-dated option, not yet evidence of material revenue or margin contribution.

Near term, the key test is whether the expected medical and defense recovery appears in reported orders and revenue, not merely management commentary. The second-half outlook also limits the case for extrapolating first-half growth. The 33% decline could be an overreaction if orders normalize, but valuation, liquidity, customer concentration, and the stock’s trading depth are not provided, so a compelling entry level cannot be established. The dividend deserves verification: compare its per-share amount and regularity with earnings and cash generation before treating it as a durable yield. A reversal in distributor sales, continued product-sales weakness, or a reduction in the second-half outlook would falsify the recovery thesis.

Key Decisions for Investors

• Do not chase the rebound or initiate a directional position solely on the price decline. First verify valuation, trading liquidity, customer concentration, and whether distributor growth reflects end demand or channel restocking.
• Treat NVEC as a catalyst watch for the next quarter: consider a measured long only if reported medical/defense orders recover and product sales stabilize; reassess if product weakness persists or management cuts the second-half outlook.
• Monitor distributor sell-through, major-customer inventory commentary, and defense procurement timing. These indicators matter more than early design-win announcements until they translate into repeat orders.
• Verify whether the $1 quarterly dividend is recurring and assess coverage against earnings and operating cash flow. Any cut or evidence that the payout is not supported by recurring cash generation would undermine the income-support thesis.